Abstract
We characterized the extent and timing of tumor necrosis factor (TNF) α-system activation during multiple sclerosis (MS). We measured serum levels of soluble TNFOC, soluble TNFαreceptor 1 (R1) and soluble TNFα receptor 2 (R2) in 65 MS patients in different phases of disease and we found no differences between MS patients and healthy controls and no correlation with clinical relapses, presence of gadolinium-enhancing brain-magnetic resonance imaging (MRI) lesions and bioactivity of TNFa. We also measured, in 8 additional MS patients peripheral blood mononuclear cells (PBMC) mRNA and serum levels of TNFCX, Rl and R2 every 15 days for 5 menths aerear elinical evcavhation PRMC TNFα R1 and R2 mRNA and serum levels of soluble Rl and R2, but not TNFa, fluctuated concordantly (p
| Original language | English |
|---|---|
| Pages (from-to) | 77 |
| Number of pages | 1 |
| Journal | Italian Journal of Neurological Sciences |
| Volume | 18 |
| Issue number | 4 |
| Publication status | Published - 1997 |
Fingerprint
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Neurology
Cite this
Tumor necrosis factor O and its receptors in multiple sclerosis. / Martino, G.; Consiglio, A.; Corti, A.; Sciacca, F. L.; Grimaldi, L. M E.
In: Italian Journal of Neurological Sciences, Vol. 18, No. 4, 1997, p. 77.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tumor necrosis factor O and its receptors in multiple sclerosis
AU - Martino, G.
AU - Consiglio, A.
AU - Corti, A.
AU - Sciacca, F. L.
AU - Grimaldi, L. M E
PY - 1997
Y1 - 1997
N2 - We characterized the extent and timing of tumor necrosis factor (TNF) α-system activation during multiple sclerosis (MS). We measured serum levels of soluble TNFOC, soluble TNFαreceptor 1 (R1) and soluble TNFα receptor 2 (R2) in 65 MS patients in different phases of disease and we found no differences between MS patients and healthy controls and no correlation with clinical relapses, presence of gadolinium-enhancing brain-magnetic resonance imaging (MRI) lesions and bioactivity of TNFa. We also measured, in 8 additional MS patients peripheral blood mononuclear cells (PBMC) mRNA and serum levels of TNFCX, Rl and R2 every 15 days for 5 menths aerear elinical evcavhation PRMC TNFα R1 and R2 mRNA and serum levels of soluble Rl and R2, but not TNFa, fluctuated concordantly (p
AB - We characterized the extent and timing of tumor necrosis factor (TNF) α-system activation during multiple sclerosis (MS). We measured serum levels of soluble TNFOC, soluble TNFαreceptor 1 (R1) and soluble TNFα receptor 2 (R2) in 65 MS patients in different phases of disease and we found no differences between MS patients and healthy controls and no correlation with clinical relapses, presence of gadolinium-enhancing brain-magnetic resonance imaging (MRI) lesions and bioactivity of TNFa. We also measured, in 8 additional MS patients peripheral blood mononuclear cells (PBMC) mRNA and serum levels of TNFCX, Rl and R2 every 15 days for 5 menths aerear elinical evcavhation PRMC TNFα R1 and R2 mRNA and serum levels of soluble Rl and R2, but not TNFa, fluctuated concordantly (p
UR - http://www.scopus.com/inward/record.url?scp=33746356247&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746356247&partnerID=8YFLogxK
M3 - Article
VL - 18
SP - 77
JO - Italian Journal of Neurological Sciences
JF - Italian Journal of Neurological Sciences
SN - 0392-0461
IS - 4
ER -